NCT05007236 - Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection. | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions

SARS-CoV-2 Infection

Interventions

DRUG

RP7214 + Standard of care (SOC)

RP7214 tablets will be administered orally twice a day for 14 days

DRUG

Placebo + Standard of care (SOC)

Placebo will be administered orally twice a for 14 days

Trial Locations (16)

Citizen Hospital, Bangalore

Madhu Superspeciality Hospital & Research Center, Bangalore

Rajalakshmi Hospital & Research Center, Bangalore

Panimalar medical college hospital and research institute, Chennai

Maharaja Agrasen Superspeciality Hospital, Jaipur

Nil Ratan Sircar Medical College and Hospital, Kolkata

Malabar Medical College, Kozhikode

BAJ RR Hospital & Research center, Mumbai

DEC Healthcare Hospital, Nellore

Vijaya Super specialty Hospital, Nellore

Jivanrekha Multispeciality Hospital, Pune

PCMC'S PGI Yashwantrao Chavan Memorial Hospital, Pune

Sant Dnyaneshwar Hospital (Accord Multispeciality Hospital), Pune

Govt General Hospital, Srikakulam

Great Eastern medical school and hospital, Srikakulam

King George Hospital, Visakhapatnam